General Information of the Drug (ID: M6APDG03229)
Name
BTS-67582
Synonyms
1,1-Dimethyl-2-(2-morpholinophenyl)guanidine fumarate
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
3D MOL
Formula
C17H24N4O5
InChI
1S/C13H20N4O.C4H4O4/c1-16(2)13(14)15-11-5-3-4-6-12(11)17-7-9-18-10-8-17;5-3(6)1-2-4(7)8/h3-6H,7-10H2,1-2H3,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1+
InChIKey
FFEKJBVVAJTQST-WLHGVMLRSA-N
PubChem CID
9885406
TTD Drug ID
D0P2MH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sulfonylurea receptor 2 (ABCC9)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for BTS-67582. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BTS-67582 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). [1], [2]
References
Ref 1 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the Beta-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis. 2020 May 7;9(5):45. doi: 10.1038/s41389-020-0229-9.
Ref 2 Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes